240 related articles for article (PubMed ID: 31149909)
21. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
22. The pagetoid variant of urothelial carcinoma in situ.
Orozco RE; Vander Zwaag R; Murphy WM
Hum Pathol; 1993 Nov; 24(11):1199-202. PubMed ID: 8244321
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review.
Casey RG; Catto JW; Cheng L; Cookson MS; Herr H; Shariat S; Witjes JA; Black PC
Eur Urol; 2015 May; 67(5):876-88. PubMed ID: 25466937
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
26. BK polyomavirus and urothelial carcinoma: Experience at a tertiary care centre in India with review of literature.
Kumari K; Pradeep I; Kakkar A; Dinda AK; Seth A; Nayak B; Singh G
Ann Diagn Pathol; 2019 Jun; 40():77-80. PubMed ID: 31075667
[TBL] [Abstract][Full Text] [Related]
27. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
28. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis.
Orozco RE; Martin AA; Murphy WM
Cancer; 1994 Jul; 74(1):115-22. PubMed ID: 8004567
[TBL] [Abstract][Full Text] [Related]
29. Significance of denuded urothelium in papillary urothelial lesions.
Owens CL; Epstein JI
Am J Surg Pathol; 2007 Feb; 31(2):298-303. PubMed ID: 17255776
[TBL] [Abstract][Full Text] [Related]
30. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Alston ELJ; Zynger DL
Diagn Pathol; 2019 Aug; 14(1):91. PubMed ID: 31419984
[TBL] [Abstract][Full Text] [Related]
31. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
[TBL] [Abstract][Full Text] [Related]
32. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
33. Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion.
Han L; Gallan A; Paner GP
Am J Surg Pathol; 2019 Apr; 43(4):475-479. PubMed ID: 30475253
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of atypical papillary urothelial hyperplasia.
Swierczynski SL; Epstein JI
Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
[TBL] [Abstract][Full Text] [Related]
35. [Epidermoid carcinoma of the urinary tract. Immunohistochemical study].
Salas Valien JS; García Díez F; González Morán MA; Rodríguez López JA; Guerreiro González R
Arch Esp Urol; 1990; 43(9):973-6. PubMed ID: 1708980
[TBL] [Abstract][Full Text] [Related]
36. Observations on Aron et al's "Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia".
Fellegara G; Gabba S; Dorji T; De Luca G; Colecchia M
Am J Surg Pathol; 2014 Jul; 38(7):1013-5. PubMed ID: 24618606
[No Abstract] [Full Text] [Related]
37. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.
Ather MH; Nazim SM
Korean J Urol; 2015 Aug; 56(8):553-64. PubMed ID: 26279824
[TBL] [Abstract][Full Text] [Related]
38. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
39. Iatrogenic pathology of the urinary bladder.
Lopez-Beltran A; Montironi R; Raspollini MR; Cheng L; Netto GJ
Semin Diagn Pathol; 2018 Jul; 35(4):218-227. PubMed ID: 29576423
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
